Health Condition 1: null- Advanced stage non small cell lung cancer (NSCLC) patients treated with platinum based chemotherapy.
Conditions
Interventions
None listed
Sponsors
Tata Memorial Hospital
Eligibility
Inclusion criteria
Inclusion criteria: INCLUSION CRITERIA: Lung cancer patients (age >18 years) who are started on platinum based chemotherapy.
Exclusion criteria
Exclusion criteria: EXCLUSION CRITERIA: 1. Age 2. Patients in whom therapy is discontinued prior to completion of 6 weeks due to any reason. 3. Presence of any thromboembolic event before start of chemotherapy including deep venous thrombosis (DVT), pulmonary embolus, cerebrovascular accident, and unstable angina/myocardial infarction (MI). 4.Patients with bleeding diathesis, inherited coagulopathy, and those requiring therapeutic anticoagulation, regular nonsteroidal anti-inflammatory drugs, and aspirin. 5. Patients receiving angiogenesis inhibitor drug- bevacizumab.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PRIMARY OUTCOME: The overall incidence, timing, and characteristics of thromboembolic events (venous or arterial) in adult patients of advanced stage non small cell lung cancer treated with platinum-based chemotherapy. Timepoint: At the baseline and end of the study(4 weeks from the last dose of chemotherapy) or earlier in case of development of a thromboembolic event . | — |
Secondary
| Measure | Time frame |
|---|---|
| SECONDARY OUTCOME: Secondary objectives are to analyze the prognostic value of baseline and treatment characteristics in predicting the occurrence of a thromboembolic events in patients of advanced stage non small cell lung cancer treated with platinum-based chemotherapy. Timepoint: At the baseline and end of the study(4 weeks from the last dose of chemotherapy) or earlier in case of development of a thromboembolic event . | — |
Countries
India
Contacts
Public ContactDr Amit Joshi
Tata Memorial Hospital
Outcome results
None listed